Australian Pesticides and Veterinary Medicines Authority

Section	on 1: Entity overview and resources	125
1.1	Strategic direction statement	125
1.2	Entity resource statement	127
1.3	Budget measures	129
Section	on 2: Outcomes and planned performance	130
2.1	Budgeted expenses and performance for Outcome 1	131
Section	on 3: Budgeted financial statements	136
3.1	Budgeted financial statements	136
3.2	Budgeted financial statements tables	137

Australian Pesticides and Veterinary Medicines Authority

Section 1: Entity overview and resources

1.1 Strategic direction statement

The Australian Pesticides and Veterinary Medicines Authority (APVMA) is established under the *Agricultural and Veterinary Chemicals* (*Administration*) *Act* 1992 (Administration Act). The APVMA's principal responsibilities are described in the Administration Act and the *Agricultural and Veterinary Chemicals Code Act* 1994. We support the delivery and management of the National Registration Scheme (NRS) through the responsible regulation and control of agricultural and veterinary (agvet) chemicals up to and including the point of retail sale.

Partnerships are crucial to achieving our objectives, meeting our responsibilities as part of the NRS and supporting growth in the Australian agricultural sector and trade. We are actively engaging with stakeholders in domestic and international forums on matters of agvet regulation, strengthening our relationships with regulatory partners through Memorandums of Understanding and global joint reviews, and harmonising requirements, guidance, and approaches to better align with international counterparts, as appropriate in the Australian context.

The APVMA is deeply committed to building a safe, diverse, inclusive, and high-performing culture united by the Australian Public Service Values and our purpose and values. Through the delivery of our People Strategy 2022–25 we will build a positive culture of respect, inclusiveness, and accountability and strengthen the agility of our organisation to respond to emerging risks and opportunities. We will continue to deliver contemporary training and development solutions to support our people to attain the skills and capabilities required to achieve our purpose, objectives, priorities, and values.

Technology continues to advance at an increasingly rapid pace. Innovations in precision agriculture and smart farming continue to provide farmers with more effective and efficient ways of managing their farms and new approach methodologies are reducing our reliance on vertebrate animal testing and improving the reliability of data. Safer, more effective veterinary vaccines are being produced using messenger ribonucleic acid (mRNA) technology. The APVMA will need to respond quickly, technically and within our legislative mandate, to this evolving landscape.

Our ability to make scientifically robust and timely regulatory decisions is dependent on our highly capable staff as well as the regulatory platform, tools and systems that enable us to provide them. These systems must be designed to support and enhance the user, enabling them to engage more effectively with information and services today, and into the future.

Budget 2023–24 | Portfolio Budget Statements

The ongoing and effective management of our information and communications technology (ICT) infrastructure and services through a fit-for-purpose managed services arrangement is the backbone of our forward operations. Working in partnership with our stakeholders, the APVMA is implementing significant reform to ensure the reliability and sustainability of our ICT services.

1.2 Entity resource statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, please refer to *Budget Paper No. 4: Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: Australian Pesticides and Veterinary Medicines Authority – Resource Statement – Budget Estimates for 2023–24 as at May Budget 2023

Statement – Budget Estimates for 2023–24 as at May Bu	dget 2023	
	2022–23	2023–24
	Estimated	Estimate
	actual	
	\$'000	\$'000
Opening balance/cash reserves at 1 July	149	80
Funds from Government		
Annual appropriations – ordinary annual services (a)		
Outcome 1	1,663	1,840
Total annual appropriations	1,663	1,840
Special appropriations ^(b)		
Agricultural and Veterinary Chemicals (Administration) Act 1992,		
s. 58 (6)	41,866	43,988
Total special appropriations	41,866	43,988
Amounts received from related entities		
Amounts from portfolio department ^(c)	138	144
Total amounts received from related entities	138	144
Total funds from Government	43,667	45,972
Funds from industry sources		
Levies, fees and charges ^(d)	41.866	43,988
less amounts paid to the CRF	(41,866)	(43,988)
Total funds from industry sources	-	-
Funds from other sources		
Other	411	202
Total funds from other sources	411	202
Total net resourcing for APVMA	44,227	46,254
	2022–23	2023–24
Average staffing level (number)	185	190

- (a) Appropriation Bill (No. 1) 2023–24. Appropriation is provided through the Department of Agriculture, Fisheries and Forestry (DAFF) and is specified within the Annual Appropriation Bills as a payment to APVMA and is considered departmental for all purposes.
- (b) APVMA's special appropriation is not directly appropriated as it is a corporate Commonwealth entity (CCE) under the *Public Governance*, *Performance and Accountability Act 2013* (PGPA Act). Appropriations are made to DAFF and are then paid to APVMA and are considered departmental for all purposes.
- (c) Funding provided by the portfolio department that is not specified within the Annual Appropriation Bills as a payment to that CCE (for example, a grant awarded to a CCE from one of its portfolio department's administered programs).
- (d) These charges are imposed by the Agricultural and Veterinary Chemicals Code Act 1994 and the Agricultural and Veterinary Chemical Products (Collection of Levy) Act 1994. They are collected by APVMA and transferred to the Consolidated Revenue Fund (CRF). These amounts are then drawn down by the department as a special appropriation under the Administration Act.

Please note: All figures shown above are GST exclusive – these may not match figures in the cash flow statement.

Prepared on a resourcing (i.e., appropriations available) basis.

1.3 Budget measures

Budget measures in Part 1 relating to the Australian Pesticides and Veterinary Medicines Authority are detailed in *Budget Paper No.* 2 and are summarised below.

Table 1.2: Australian Pesticides and Veterinary Medicines Authority – 2023–24 Budget Measures

Part 1: Measures announced since the 2022-23 October Budget

Australian Pesticides and Veterinary Medicines Authority does not have any 2023-24 Budget measures.

Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance*, *Performance and Accountability Act* 2013. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity's planned and actual performance.

APVMA's most recent corporate plan can be found at:

https://www.transparency.gov.au/sites/default/files/reports/2022-

23_australian_pesticides_and_veterinary_medicines_authority_corporate_plan.pdfhttp://www.agriculture.gov.au/about/reporting/corporate-plan.

APVMA's most recent annual performance statement can be found at:

https://www.transparency.gov.au/annual-reports/australian-pesticides-and-veterinary-medicines-authority/reporting-year/2021-22 in chapter 3.

2.1 Budgeted expenses and performance for Outcome 1

Outcome 1: Protection of the health and safety of people, animals, the environment, and agricultural and livestock industries through regulation of pesticides and veterinary medicines.

2.1.1: Linked programs

Department of Agriculture, Fisheries and Forestry

Program 1.10: Agricultural Resources

Contribution to Outcome 1 made by linked programs:

APVMA and DAFF work together to ensure the protection of the health and safety of humans, animals, and the environment.

2.1.2: Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1: Budgeted expenses for Outcome 1

Outcome 1: Protection of the health and safety of	of people,	animals, th	ne environr	nent, and
agricultural and livestock industries through regulation	n of pestic	ides and vet	erinary med	icines.
2022–23	2023-24	2024-25	2025-26	2026-27

	Estimated actual	Budget	Forward estimate	Forward estimate	Forward estimate			
	\$'000	\$'000	\$'000	\$'000	\$'000			
Program 1.1: Australian Pesticides and Veterinary Medicines Authority								
Revenue from Government Ordinary annual services								
(Appropriation Bill (No. 1)) ^(a)	1,663	1,840	2,265	2,414	1,783			
Payment from related entities Special appropriations	138	144	148	150	153			
Agricultural and Veterinary Chemicals (Administration) Act 1992, s. 58 (6) –								
amount payable to the APVMA	45,287	41,794	42,164	42,541	42,926			
Revenues from other independent sources Expenses not requiring appropriation in the	328	114	115	116	117			
Budget year ^(b)	(3,537)	141	96	67	18			
Total expenses for program 1.1	43,879	44,033	44,788	45,288	44,997			

Outcome 1 totals by resource type					
Revenue from Government Ordinary annual services					
(Appropriation Bill (No. 1)) ^(a)	1,663	1,840	2,265	2,414	1,783
Payment from related entities	138	144	148	150	153
Special appropriations	45,287	41,794	42,164	42,541	42,926
Revenues from other independent sources	328	114	115	116	117
Expenses not requiring appropriation in the					
Budget year ^(b)	(3,537)	141	96	67	18
Total expenses for Outcome 1	43,879	44,033	44,788	45,288	44,997

	2022-23	2023-24
Average staffing level (number)	185	190

⁽a) Appropriation Bill (No. 1) 2023-24. APVMA is CCE under the PGPA Act and does not receive direct appropriations. Appropriation is provided through DAFF and is specified with the Annual Appropriation Bills as payment to APVMA and is considered departmental for all purposes.

Departmental appropriation splits and totals are indicative estimates and may change in the course of the budget year as government priorities change.

⁽b) 'Expenses not requiring appropriation in the budget year' are made up of make good expenses, audit fees, and can include depreciation / amortisation expenses not requiring an appropriation.

Table 2.2: Performance measure for Outcome 1

Table 2.2 details the performance measures for each program associated with Outcome 1. It also provides the related key activities as expressed in the current corporate plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, the 2023–24 Budget measures that have created new programs or materially changed existing programs are provided.

environment, an	otection of the health and safety of people, animals, the add agricultural and livestock industries through regulation of eterinary medicines.
Program 1.1: Aus	stralian Pesticides and Veterinary Medicines Authority
Objective	APVMA regulates agricultural and veterinary chemicals to manage the risks of pests and diseases for the Australian community and to protect Australia's trade and the health and safety of people, animals, and the environment.
Key Activities	Achievement of the APVMA Objective is achieved through our six strategic Objectives, each supported by a range of key activities.
	Trusted Regulator Risk-based assessment and registration of pesticides and veterinary chemicals Identification and review of the safety of existing chemicals of regulatory concern Quality audits of application decisions and decision-making process Implementation of the APVMA Stakeholder Engagement Framework Engagement with domestic partners on agvet biosecurity matters. Respected partner, nationally and internationally Active engagement in domestic and international forums on matters of agvet regulation Strengthen our relationship with domestic and international regulatory partners through memorandum of understanding, trilateral reviews, and joint activities. Harmonise requirements, guidance, and approach to better align with international counterparts, as appropriate in the Australian context.

Table 2.2: Performance measure for Outcome 1 (continued)

Key Activities (continued) 3. Contemporary regulatory system Implementation of measures outlined in the Improvement Ongoing implementation of key improvement projects such Tailored Guidance, Permit to Label, and Agvet Labelling On Actively participate in method and technique development Agvet chemical risk assessment Engage with, and contribute to, the development of contemporary policies for agvet chemical regulation. 4. Superior 'over the horizon' capability Engagement with domestic and international partners on emerging technology and advances on agvet chemical formulations and delivery systems (e.g. ribonucleic acid (Rinterference)) Active engagement in discussions on emerging issues, exotic pest incursions, climate and population pressures, mRNA, mono-clonal vaccines etc.					
	support a modern regulatory environment. 5. Operational excellence				
	 Maintain pragmatic science-based risk assessment along wrisk-mitigation approaches Ongoing implementation of the Quality Management Frame Maintain a robust peer-review and application approval process. Attracting, developing and retaining the best people Implementation of the APVMA People Strategy 2022–2025 Implementation of the APVMA Culture Pulse Check Roadm 2023–2025. 				
Year	Performance measures Expected Performance Res	ults			
Current year 2022–23	Percentage of applications finalised within statutory timeframes. 97 per cent.				
Year	Performance measures Planned Performance Resu	Its			
Budget Year 2023–24	Proportion of applications finalised within legislative timeframes. 90 per cent.				
	Proportion of applications that pass quality audits under the Quality Management Framework. 95 per cent.				

Table 2.2: Performance measure for Outcome 1 (continued)

Year	Performance measures	Planned Performance Results			
Budget Year 2023–24 (continued)	report they are satisfied with the				
	Proportion of committed reform projects implemented within the required timeframes.	80 per cent.			
Forward	Measure	2024–25	2025–26	2026–27	
Estimates 2024–27	Proportion of applications finalised within legislative timeframes.	90 per cent.			
	Proportion of applications that pass quality audits under the Quality Management Framework.	95 per cent.			
	Proportion of stakeholders that report they are satisfied with the quality of engagements with the APVMA.				
	Proportion of committed reform projects implemented within the required timeframes.		80 per cent.		

Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2023–24 budget year, including the impact of budget measures and resourcing on financial statements.

3.1 Budgeted financial statements

3.1.1: Differences between entity resourcing and financial statements

The resourcing statement is prepared on a cash basis. The financial statements are prepared on an accrual basis. Differences between the resourcing and financial statements represent timing differences between revenue recognition and cash received.

3.1.2: Explanatory notes and analysis of budgeted financial statements

Revenue forecasts for the 2022–23 financial year have been revised following sales declarations lodged by industry during the year. his has seen an increase to APVMA's revenue over the original estimate, which is now shown in the following financial tables.

3.2 Budgeted financial statements tables

Table 3.1: Comprehensive income statement (showing net cost of services) (for the period ended 30 June)

	2022–23	2023–24	2024–25	2025–26	2026–27
	Estimated	Budget	Forward	Forward	Forward
	actual	#1000	estimate	estimate	estimate
	\$'000	\$'000	\$'000	\$'000	\$'000
EXPENSES					
Employee benefits	27,229	28,185	29,063	30,039	30,265
Suppliers	13,828	12,926	13,112	12,259	11,755
Depreciation and amortisation	2,653	2,765	2,469	2,858	2,858
Finance costs	169	157	144	132	119
Total expenses	43,879	44,033	44,788	45,288	44,997
LESS:					
OWN-SOURCE INCOME					
Own-source revenue					
Other	328	114	115	116	117
Total own-source revenue	328	114	115	116	117
Total own-source income	328	114	115	116	117
Net cost of (contribution by) services	43,551	43,919	44,673	45,172	44,880
Revenue from Government					
Commonwealth contribution	1,663	1,840	2,265	2,414	1,783
Industry contributions	45,287	41,794	42,164	42,541	42,926
Payment from related entities	138	144	148	150	153
Total revenue from Government	47,088	43,778	44,577	45,105	44,862
Surplus/(deficit) attributable to the					
Australian Government	3,537	(141)	(96)	(67)	(18)
Total comprehensive income/(loss)					
attributable to the Australian					
Government	3,537	(141)	(96)	(67)	(18)
Note: Impact of net cash appropriation are	rangements				
	2022–23	2023–24	2024–25	2025–26	2026–27
	\$'000	\$'000	\$'000	\$'000	\$'000
Total comprehensive income/(loss)					
excluding depreciation/amortisation					
expenses previously funded through					
revenue appropriations, depreciation on					
ROU, principal repayments on					
leased assets	3,731	-	-	-	-
less depreciation/amortisation expenses					
for ROU ^(a)	1,255	1,255	1,177	987	987
add principal repayments on leased					
assets ^(a)	1,061	1,114	1,081	920	969
Total comprehensive income/(loss) -					
as per the Statement of comprehensive					
income	3,537	(141)	(96)	(67)	(18)

⁽a) Applies to leases under Australian Account Standards Board (AASB) 16 Leases. Right of Use (ROU).

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

	2022–23	2023–24	2024–25	2025–26	2026–27
	Estimated	Budget	Forward	Forward	Forward
	actual		estimate	estimate	estimate
	\$'000	\$'000	\$'000	\$'000	\$'000
ASSETS					
Financial assets					
Cash and cash equivalents	80	370	700	610	610
Trade and other receivables	35,752	33,414	34,226	36,037	37,758
Total financial assets	35,832	33,784	34,926	36,647	38,368
Non-financial assets					
Land and buildings	13,673	12,116	10,637	9,348	8,059
Property, plant and equipment	568	293	208	123	38
Intangibles	2,703	5,328	4,573	3,239	1,905
Other non-financial assets	825	825	825	825	825
Total non-financial assets	17,769	18,562	16,243	13,535	10,827
Total assets	53,601	52,346	51,169	50,182	49,195
LIABILITIES					
Payables					
Suppliers	1,104	1,104	1,104	1,104	1,104
Other payables	1,151	1,151	1,151	1,151	1,151
Total payables	2,255	2,255	2,255	2,255	2,255
Interest bearing liabilities					
Leases	12,115	11,001	9,920	9,000	8,031
Total interest bearing liabilities	12,115	11,001	9,920	9,000	8,031
Provisions					
Employee provisions	5,412	5,412	5,412	5,412	5,412
Total provisions	5,412	5,412	5,412	5,412	5,412
Total liabilities	19,782	18,668	17,587	16,667	15,698
Net assets	33,819	33,678	33,582	33,515	33,497
EQUITY*					
Parent entity interest					
Reserves	279	279	279	279	279
Retained surplus/(accumulated deficit)	33,540	33,399	33,303	33,236	33,218
Total parent entity interest	33,819	33,678	33,582	33,515	33,497
Total Equity	33,819	33,678	33,582	33,515	33,497

^{*&#}x27;Equity' is the residual interest in assets after deduction of liabilities.

Table 3.3: Departmental statement of changes in equity — summary of movement (Budget year 2023–24)

	Retained	Asset	Total
	earnings	revaluation	equity
		reserve	
	\$'000	\$'000	\$'000
Opening balance as at 1 July 2023			
Balance carried forward from previous period	33,540	279	33,819
Adjusted opening balance	33,540	279	33,819
Comprehensive income			
Surplus/(deficit) for the period	(141)	-	(141)
Total comprehensive income	(141)	-	(141)
of which:			
Attributable to the Australian Government	(141)	-	(141)
Estimated closing balance as at			
30 June 2024	33,399	279	33,678
Closing balance attributable to the Australian			
Government	33,399	279	33,678

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

	2022–23	2023–24	2024–25	2025–26	2026–27
	Estimated	Budget	Forward	Forward	Forward
	actual		estimate	estimate	estimate
	\$'000	\$'000	\$'000	\$'000	\$'000
OPERATING ACTIVITIES					
Cash received					
Revenue from Government	43,667	45,972	43,617	43,144	42,988
Net GST received	1,414	1,365	1,082	1,056	1,079
Other	411	202	206	208	211
Total cash received	45,492	47,539	44,905	44,408	44,278
Cash used					
Employees	27,201	28,185	29,063	30,039	30,265
Suppliers	15,070	14,235	14,137	13,257	12,775
Interest payments on lease liability	169	157	144	132	119
Total cash used	42,440	42,577	43,344	43,428	43,159
Net cash from (used by)					
operating activities	3,052	4,962	1,561	980	1,119
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and					
equipment and intangibles	2,060	3,558	150	150	150
Total cash used	2,060	3,558	150	150	150
Net cash from (used by)					
investing activities	(2,060)	(3,558)	(150)	(150)	(150)
FINANCING ACTIVITIES					
Cash used					
Principal payments on lease liability	1,061	1,114	1,081	920	969
Total cash used	1,061	1,114	1,081	920	969
Net cash from (used by)					
financing activities	(1,061)	(1,114)	(1,081)	(920)	(969)
Net increase (decrease) in cash held	(69)	290	330	(90)	-
Cash and cash equivalents at the	`				
beginning of the reporting period	149	80	370	700	610
Cash and cash equivalents at the end of					
the reporting period	80	370	700	610	610

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

	2022–23	2023–24	2024–25	2025–26	2026–27
	Estimated	Budget	Forward	Forward	Forward
		Budget			
	actual	41000	estimate	estimate	estimate
	\$'000	\$'000	\$'000	\$'000	\$'000
PURCHASE OF NON-FINANCIAL ASSETS					
Funded internally from departmental					
resources ^(a)	2,060	3,558	150	150	150
TOTAL	2,060	3,558	150	150	150
RECONCILIATION OF CASH USED TO					
ACQUIRE ASSETS TO ASSET					
MOVEMENT TABLE					
Total purchases	2,060	3,558	150	150	150
Total cash used to acquire assets	2,060	3,558	150	150	150

⁽a) Includes the following s74 external revenue:

- internally developed assets;
- proceeds from the sale of assets.

Consistent with information contained in the Statement of Asset Movements and the Budgeted Statement of Cash Flows.

Budget 2023–24 | Portfolio Budget Statements

Table 3.6: Statement of departmental asset movements (Budget year 2023–24)

	Building	Other	Intangibles	Total
	3	property,	3	
		plant and		
		equipment		
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2023				
Gross book value	3,313	1,666	11,441	16,420
Accumulated depreciation/amortisation				
and impairment	(872)	(1,098)	(8,738)	(10,708)
Accumulated depreciation/amortisation				
and impairment – ROU ^(a)	(4,845)	-	-	(4,845)
Opening net book balance	13,673	568	2,703	16,944
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or				
replacement assets				
By purchase – other ^(a)	-	60	3,498	3,558
Total additions	-	60	3,498	3,558
Other movements				
Depreciation/amortisation expense	(302)	(335)	(873)	(1,510)
Depreciation/amortisation expense –				
ROU ^(b)	(1,255)	-	-	(1,255)
Total other movements	(1,557)	(335)	(873)	(2,765)
As at 30 June 2024				
Gross book value	3,313	1,726	14,939	19,978
Accumulated depreciation/amortisation				
and impairment	(1,174)	(1,433)	(9,611)	(12,218)
Accumulated depreciation/amortisation				
and impairment – ROU ^(b)	(6,100)	-	-	(6,100)
Closing net book balance	12,116	293	5,328	17,737

⁽a) Applies to leases under AASB 16 Leases. Right of Use (ROU).(b) 'By purchase – other' refers to funding provided through other internal funding sources.